SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has expanded the clinical footprint of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital, Mithakhali, in Ahmedabad, India. The program began with a robotic left internal mammary artery (LIMA) take-down performed by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, using the SSi Mantra 3.0 system.
The procedure, supported by the SS Innovations team, represents a significant step in advancing robotic cardiac surgery in the region. In a LinkedIn post, the company congratulated the team and expressed gratitude for their trust and commitment, stating, “At SS Innovations International, Inc. we remain committed to enabling hospitals and…” The full post can be accessed here.
This expansion comes as SS Innovations reported 238 SSi Mantra systems installed as of September 8, up 42% from the end of 2025. The system is now installed across 12 countries, with recent expansion into Colombia, Sri Lanka, and the Philippines. The company is also pursuing U.S. FDA review and European Union CE marking as it seeks to expand SSi Mantra into additional international markets.
The adoption of robotic cardiac surgery at HCG Hospital highlights the growing global demand for advanced surgical technologies. For investors and the medical community, this news underscores SS Innovations’ commitment to innovation and its potential to capture a larger share of the robotic surgery market. As the company continues to gain regulatory approvals and expand into new geographies, its SSi Mantra system could become a key player in transforming cardiac care worldwide.
For more details on this development, see the full announcement here. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII.
InvestorWire, a specialized communications platform, distributed this announcement. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers editorial syndication to 5,000+ outlets and corporate communications solutions. For full terms, see https://www.InvestorWire.com/Disclaimer.
